The potential role of A 1 adenosine receptors in modulating neuromuscular transmission in the detrusor muscle of the urinary bladder has been tested in human and murine preparations with the intent to determine the viability of using adenosine receptor purinoceptor mediated excitatory junctional potentials (EJPs) recorded with intracellular microelectrodes were reduced in amplitude by CPA and adenosine with no effect on the spontaneous EJP amplitudes (sEJPs), confirming the prejunctional action of these agents. 8-Cyclopentyltheophylline (CPT) a selective A 1 receptor antagonist reversed the effects of CPA on EJP amplitudes with no effect of sEJPs, confirming the role of A 1 receptors in mediating these effects.
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Introduction
Overactive bladder (OAB) is a urinary bladder voiding dysfunction comprised of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, that affects 8.0-25.8% of the population (Irwin et al., 2011 . Normal function of the urinary bladder is dependent on the coordinated control of both the urinary bladder detrusor muscles and the sphincter muscles surrounding the bladder neck. Neuronal control of detrusor muscle contraction is exerted by parasympathetic cholinergic neurons (Thompson, 2004) . Agents that block muscarinic receptors, which act by inhibiting neuromuscular transmission to the urinary bladder by blocking post-junctional muscarinic receptors in the detrusor muscle, are the first line of therapeutic agents prescribed for OAB treatment. However, up to 75% of patients treated with anti-muscarinic drugs discontinue their use, either due to poor tolerance of their side effects or because of a lack of efficacy (Kelleher et al., 1997; Chapple, 2000; Chancellor et al., 2013) .
Botulinum toxin A (BotxA) has recently been introduced as a treatment for OAB; it is thought that BotxA treatment inhibits neurotransmission by blocking acetylcholine (ACh) release from the cholinergic nerves innervating the detrusor muscle (e.g. Lawrence, JPET # 228882 anti-muscarinic agents or β 3 agonists such as mirabegron (Mybetriq®) (Yamaguchi et al. 2014 ).
Promising potential targets for OAB therapy include the inhibitory purinergic receptors.
Inhibitory effects of adenosine on neurotransmitter release were first demonstrated at the rat skeletal neuromuscular junction by Ginsborg and Hirst (1972) . These and subsequent studies demonstrated that the inhibition of acetylcholine (ACh) release by adenosine at the skeletal neuromuscular junction is mediated via A 1 type adenosine receptors (Redman and Silinsky, 1993; Correia-de-Sá et al., 1996 : Silinsky, 2004 ).
Evidence for A 1 receptors affecting detrusor neurotransmission has been found in mouse bladder contraction studies (Acevedo et al., 1992) , as well as in brief reports in human and guinea pig detrusor preparations (Ikeda et al., 2004) .
In normal, healthy subjects, human detrusor neurotransmission is mediated entirely through muscarinic receptors while P2X purinoreceptors have been implicated in diseases of the human bladder (see Ford and Cockayne, 2011) . As neurotransmission in the murine detrusor muscle is mediated by both P2X purinoreceptors and muscarinic receptors (see e.g. Searl and Silinsky, 2012a) , the mouse detrusor represents a valuable tool for the study of P2X receptors. In addition, the presence of a P2X mediated component of neurotransmission (P2X receptors are ligand-gated cation channels) allows the use of electrophysiological recording (Hoyle and Burnstock, 1985; Fujii, 1988; Brading and Mostwin, 1989; Bramich and Brading, 1996; 2012a) . Specifically, evoked responses measured as electrically-evoked excitatory junctional potentials (EJPs) and spontaneous EJPs (sEJPs) can both be measured, thereby allowing quantal analysis of changes in neuromuscular transmission to be JPET # 228882 determined in murine detrusor preparations (Searl and Silinsky, 2012a) . This electrophysiological approach has proven useful in the past to enhance our understanding of the cellular mechanisms underlying neuromuscular modulation (Silinsky, 2004) and can be used to facilitate the examination of the mechanisms regulating parasympathetic transmission in the mammalian bladder (Searl and Silinsky, 2012a) .
The purpose of this study was to determine the role of A 1 adenosine receptors on detrusor transmission in both human and murine muscle, and to test the effects of A 1 receptor activation on the quantal release of ATP in murine detrusor muscle using electrophysiological methods. For the animal studies, the methods used for anesthesia and exsanguinations are in accordance with guidelines laid down by the institutional animal welfare committees of Northwestern University and Southern Illinois University Medical School and the National Institutes of Health; Institute of Laboratory Animal Resources, Committee for the update of the guide for the care and use of laboratory animals (2011). Briefly, female mice (B6129F2J, Jackson Laboratories; 20-30 g in weight), were anaesthetized with 5% isoflurane for 3-5 minutes, until unresponsive to touch, followed by cervical dislocation and exsanguination. The urinary bladder was removed and placed in a balanced salt solution containing (mM) NaCl, 137; KCl, 5; CaCl 2 , 2; MgCl 2 , 2; HEPES, 30; NaH 2 CO 3 , 24; NaH 2 PO 4 , 1; dextrose, 11 (pH 7.2 to 7.4), and gassed with O 2 in a Sylgard-lined chamber (silicone elastomer, Dow Corning Corporation, Midland, MI, USA; volume approximately 4 ml). The bladder was dissected along the ventral wall with a longitudinal incision from the bladder neck (posterior) to the top of the dome (anterior) and the bladder was opened and pinned flat, interior surface uppermost.
Unless otherwise stated, the urothelium and suburothelium were removed with careful JPET # 228882 dissection.
Contraction studies. The detrusor tissues utilized in these experiments were donated by 4 female and 17 male patients. The human detrusor muscle was cut into strips (4-8 mm x 15-20 mm) and mounted using silk sutures in 10 ml tissue baths (World Precision Instruments). Electric field stimulation (EFS) (0.05 ms square pulse duration; 5, 10, 20
Hz, 5s, and 120s apart) was applied via Ag/AgCl electrodes and delivered from a Grass Instruments stimulator (S48 or S88) under the control of an Arduino microprocessor board. For construction of the carbachol concentration-response curves, maximal contractile responses were obtained at the end of the experiments with application of 1mM carbachol following washout of the adenosine receptor agonist.
For the murine studies, the bladder detrusor muscle was bisected with two equal halves, and mounted with silk sutures in 10 ml tissue baths. EFS (0.05 ms duration) was applied at; 1, 5, and 10 Hz for 5s, every 120s via Ag/AgCl electrodes.
Tension measurements were made with either Radnoti or Grass FT 103 tension transducers (using a modified WPI transbridge transducer amplifier) with signals fed to Digidata 1440 and recorded via AxoScope (Molecular Devices). Hexamethonium (300 µM) was present in all contraction experiments to block ganglionic nicotinic receptors.
Electrophysiological studies. For electrophysiological experiments, the detrusor muscle was pinned, outside surface uppermost, and muscle cuts were made along the cranio-caudal axis in order to restrict muscle contractions. Silver wire electrodes were placed on the surface of the muscle sheet. The chamber was mounted on the heated In contrast with the human detrusor muscle, neurotransmission to murine detrusor muscle consists of both cholinergic and purinergic components (Searl and Silinsky, 2012a) . Indeed, contractions in response to EFS (10 Hz, 5 sec n-6) were reduced to 63 ± 8% of control following application of atropine (n=8), confirming that a substantial portion of the contractile response in the murine bladder is mediated by purinergic receptors. As concentration-contraction response curves evoked by carbachol or the selective muscarinic agonist methacholine were not affected by either adenosine (500 µM) (Fig. 3C, 3E ) or the A 1 adenosine receptor agonist CPA (3 µM) (Fig. 3B, 3D ), it appears that these adenosine agonists are working exclusively on pre-junctional loci.
This contrasts with the post-junctional effects of A 1 receptor activation seen in human colon (Fornai et al., 2009 ).
The purinergic component of neurotransmission in murine detrusor provides a means to measure both the purinergic component of neurotransmission and changes in postjunctional sensitivity to ATP by exploiting the electrically evoked EJP and spontaneous sEJP amplitudes (see Searl and Silinsky, 2012a) . As shown in Figs 4 and 5, neither adenosine nor CPA had any effect on sEJP amplitudes, demonstrating that the inhibitory effects of these A 1 adenosine receptor agonists were exclusively prejunctional. For the adenosine experiments, sEJP amplitudes were 6.1 ± 1.3 mV in control vs. 7.1 ± 1.8 mV in 1 mM adenosine (n=7). For the CPA experiments, sEJP amplitudes were 3.4 ± 1.5 mV in control vs. 4.0 ± 1.6 mV in 3 µM CPA (n=5). In contrast to the spontaneous events, the EJPs were reduced in amplitude by CPA (EC 50 179 ± 44 nM; n=5) and adenosine (EC 50 161.4 ± 31.6 µM; n=7) indicating a presynaptic inhibitory In order to confirm the role of A 1 receptors in these effects on electrically-evoked purinergic detrusor muscle EJPs, the effects CPT, a neutral A 1 antagonist (Searl and Silinsky, 2012b) were tested on the actions of CPA. As shown in Fig. 6 , CPT (10 µM) had no effect on EJP amplitudes in control experiments, but reversed the inhibition of EJP amplitudes produced by CPA (3 µM), hence confirming the role of A 1 adenosine receptors on pre-junctional parasympathetic nerve endings innervating the murine urinary bladder (Srinivas at al., 1996) The influence of urothelium derived adenosine on detrusor neurotransmission. It is known that substantial amounts of ATP are released from the urothelium (the inner wall of the urinary bladder) lining the bladder (Fergusson et al., 1997) . This ATP release is implicated as playing a major role in the sensory arm of urinary bladder in sensory nerve activation (Vlaskovska et al., 2001 ). Thus it might be possible for adenosine derived from this urothelium ATP release to affect detrusor transmission.
However, as shown in type adenosine receptors which are also present on the detrusor muscle.
As CCPA and adenosine had similar effects on the contractions evoked by EFS in both human and murine detrusor muscle, we thus used electrophysiological methods on the murine detrusor preparation in order to test for pre-junctional changes in transmitter release by adenosine and CPA on evoked purinergic EJPs amplitudes and sEJPs. Our results showed that evoked EJPs were reduced but sEJP amplitudes were unaffected by these agents, indicating a pre-junctional effect on the nerve endings innervating the The potencies of adenosine and the A 1 receptor agonists are similar to those seen at the rodent skeletal neuromuscular junction (Silinsky, 2004; Correia-de-Sá et al.,1996; Nagano et al., 1992) . It should be mentioned that one feature of adenosine receptors is that the efficacy of adenosine and adenosine agonists vary many fold between tissues depending on the numbers of spare receptors present (Fredholm, 2010; Gesztelyi, et al., 2013) . The low potencies of adenosine and the A 1 adenosine receptors agonists at the murine and human detrusor muscles suggest that the spare receptor populations in both preparations are comparatively low (Fredholm, 2010; Kiss et al., 2013; Gesztelyi et al., 2013) . In addition, the EC 50 concentrations for EJPs and for contractions were not significantly different in this preparation (see Figs 3 and 4) , suggesting that contraction studies may provide a reliable measure of the potency of pre-junctionally acting drugs in detrusor muscle preparations.
The urothelium and the underlying suburothelium are generally believed to play an important role in regulating detrusor muscle activity and play an inhibitory role in neurotransmission (Chaiyaprasithi et al., 2003 Munoz et al., 2010 . In our contraction experiments, the effects of CPA were unaffected by the presence of the urothelium, with no significant differences between the effects of CPA on EFS evoked contractions in preparations with the detrusor alone, and those where the urothelium was left intact, suggesting that there was insufficient endogenous adenosine present to affect detrusor The potential clinical benefits of A 1 adenosine receptor agonists as therapeutic treatment for overactive bladder in unclear. Thus, in one study, intravesical perfusion of sub-nanomolar concentrations of CCPA was found to significantly lower the voiding threshold in both control and cyclophosphamide treated rats (Prakasam et al., 2012) .
However, in a different study also on rats, intravesical perfusion of CCPA was found to reduce bladder overactivity induced by DMSO (Kitta et al., 2014) . 
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Specifically; in B For CPA, the EC 50 for carbachol was 251 ± 50 nM in control vs. 325 ± 49 nM in 3 µM CPA, n=5, (P=0.321); in C, the EC 50 for carbachol was 251 ± 50 nM in control vs. 325 ± 49 nM in 500 µM adenosine, n=5, (P=0.321); in D the EC 50 for methacholine was 11.2 ± 5.7 µM control vs. 3.4 ± 0.9 µM in 3 µM CPA, n=5, (P=0.214);
in E the EC 50 for methacholine was 5.5 ± 2.7 µM in control vs. 2.7 ± 0.9 µM in 500 µM adenosine; n=5 (P=0.359) and the EC 50 for carbachol was 355 ± 84 nM in control vs.
299 ± 71 nM in 500 µM adenosine (P=0.622). (n=7) and CPA (n=5) on the EFS evoked contractions (Fig. 3) and on EFS evoked EJPs were similar such that the EC 50 concentrations of adenosine and CPA for contractions and EJP were not significantly different (P= 0.126 and P = 0.076 respectively). B shows the inhibitory effects of adenosine (1mM) and CPA (3 µM) on EJP amplitudes and the lack of effect of these agents on sEJP amplitudes. receptor antagonist CPT (10 µM) had no effect on control EJP amplitudes (n=5).
However, the inhibition of EJP amplitude by CPA (3 µM) (P<0.009, ANOVA) is reversed by CPT (10 µM) (n=5). 
